Menu
Recruiting NCT05728268

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Phase II Interventional Breast Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: dose-dense nab-paclitaxel followed by EC.
Who it may be relevant to
Registry conditions: Breast Cancer. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Studies have shown that dose-dense chemotherapy reduces the risk of recurrence and death of breast cancer patients comparing with standard-schedule chemotherapy. But some research data indicate that HR+/HER2- breast cancer patients benefit from dose-dense chemotherapy while some have negative results. How to identify HR+/HER2 breast cancer patients who are more likely to benefit from dose-dense chemotherapy is strongly necessary. Ki67 is a marker reflecting the proliferation of tumor cells. Breast cancer patients with high Ki67 are more likely to benefit from dose-dense chemotherapy. The purpose of this project is to investigate the efficacy and safety of neoadjuvant dose-dense chemotherapy for HR+/HER2- breast cancer patients with high proliferation index. At the same time, we will explore biomarkers, such as MammaPrint and BluePrint, to further identify patients who benefit more from neoadjuvant dose-dense chemotherapy.

Interventions

  • Drug dose-dense nab-paclitaxel followed by EC
    dose-dense nab-paclitaxel followed by EC

Primary outcome measures

  • RCB [Time frame: 7 days]

Eligibility criteria

Inclusion criteria

  • Females with age of 18 to 70 years old.
  • Newly diagnosed breast cancer patients.
  • Planned neoadjuvant chemotherapy.
  • Hormone receptor status: Estrogen receptor (ER)-positive or Progesterone Receptor (PR)- positive.
  • HER2/neu-negative.
  • Ki67≥30%.
  • Clinical stage IIB-IIIC.
  • Informed consent form understood and signed.
  • Patient agrees to all follow-up visits.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
  • Women of childbearing potential must have a negative serum pregnancy test.

Exclusion criteria

  • Metastatic disease
  • Pregnancy.
  • Nursing mothers.
  • Active or uncontrolled infection.
  • Presence of another malignancies.
  • Granulocyte count < 1.5\*10\^9/L.
  • Platelet count < 100\*10\^9/L.
  • Hemoglobin < 90g/L.
  • Serum Creatinine more than 1.5 upper limit.
  • AST and ALT more than 2.5 upper limit.
  • LVEF< 50%.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Shantou Central Hospital — Shantou

Identifiers

NCT: NCT05728268 · ShantouCH02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗